Find Funding Opportunities

Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System Notice Number: NOT-NS-20-051 Key Dates Release Date: April 30, 2020 First Available Due Date: 01, 2020 Expiration Date: April 15, 2021 Related Announcements NOT-NS-20-074 Notice Change Eligible Activity Codes NOT-NS-20-051 PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) NOT-OD-20-026 New NIH FORMS-F" Grant Application Forms Instructions Coming Due Dates or after 25, 2020 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 Purpose NINDS issuing Notice Special Interest NOSI) highlight urgent need research Coronavirus Disease 2019 COVID-19) on biological effects the nervous system its causative agent, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2). Research interest must fall within NINDS’s scientific mission, is support basic, translational, clinical neuroscience research expand fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. Research Objectives order rapidly improve our understanding the neurological consequences infection SARS-CoV-2 of COVID-19, NINDS encouraging submission applications supplements address biology, pathophysiology, prevention, diagnosis, sequelae, treatment the 2019 Novel Coronovirus are directly related the NINDS mission. National Institute Alcohol Abuse Alcoholism NIAAA) accept supplements NIAAA-supported projects fall within scope the NOT-NS-20-051 are relevant the mission the NIAAA. Specifically, NIAAA interested studies integrate alcohol exposure research topics outlined the announcement better understand, prevent, mitigate of neurobiological consequences SARS-CoV-2 infection COVID-19 individuals have Alcohol Disorders AUD). NIAAA encourages supplements be collaborative nature include appropriate neurological expertise the proposed projects. Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 (Parent Admin Supp Clinical Trial Optional). Eligible activity codes fare limited the mechanisms listed in PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications to PA-18-935 are limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Scope defined the original specific aims, objectives, purposes a grant, methodology, approach, analyses other activities, the tools, technologies, timeframes needed meet grant's objectives. Changes include shifting research emphasis one disease area another, changing any aspects research involving vertebrate animals human subjects. you unsure whether application involve change scope, contact NINDS program director. instructions the SF424 R&R) Application Guide and PA-18-591 or PA-18-935 must followed, the following additions: funding consideration, applicants must include “NOT-NS-20-051"(without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project period the supplement must exceed year. Application budgets not exceed 200,000 direct costs. Exceptions this budget limit be only NINDS pre-approval will only approved under very rare circumstances where work immediately impact public health. Research Strategy section the application limited 6 pages parent award must active the supplement application submitted e.g. within originally reviewed approved project period), regardless the time remaining the current project. Grants multi-year funding RF1) have additional constraints. Applicants these grants should contact program official determine eligibility. applications including those multi-project activity codes) must submitted electronically using single-project application form package Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions to PA-18-591 must completed June 25, 2020 see NOT-OD-20-026 for details.) Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Competitive revision applications to PA-18-935 must the application form package the Competition ID NOT-NS-20-051-FORMS-E." FOA be reissued a NOT-NS-20-051-FORMS-F” package May 25, 2020. Submissions to PA-18-935 must completed June 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. Applications be accepted a rolling basis from April 15, 2020 April 14, 2021 5:00 PM local time of applicant organization. NOSI expires on April 15, 2021. application submitted response this NOSI is received after expiration date be withdrawn Applications must specifically address issues potential biohazards, all research must conducted compliance the health safety requirements found the NIH Grants Policy Statement. Applications are responsive the terms this Notice not considered. Investigators planning apply response this NOSI strongly encouraged contact discuss proposed research/aims the Program Official the Parent Award advance better determine appropriateness interest the NINDS.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Please contact program officer your active award. NIAAA grantees, please direct inquiries Dr. Changhai Cui changhai.cui@nih.gov).

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

HEAL Initiative: Notice Special Interest NOSI) regarding Availability Administrative Supplements Support Strategies Reduce Stigma Pain Management Opioid Disorder OUD) Treatment Notice Number: NOT-OD-20-101 Key Dates Release Date: April 23, 2020 First Available Due Date: 29, 2020 Expiration Date: 30, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Office Behavioral Social Sciences Research OBSSR) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Division Program Coordination, Planning Strategic Initiatives, Office Disease Prevention ODP) Office Research Women's Health ORWH) Purpose Notice Special Interest NOSI) calls research stigma the context chronic pain management opioid or opioid disorder OUD). part NIH’s Helping End Addiction Long Term HEAL) Initiative, NIH support supplements current HEAL awards address challenges people affected the opioid crisis stigma, discrimination prejudice related chronic pain management the context opioid and/or opioid disorder its treatment. NOSI calls applications integrate incorporate stigma research ongoing HEAL funded chronic pain OUD studies order address stigma is occurring the context chronic pain and/or OUD. Because stigma research require large clinical community networks, supplement program designed leverage many networks already being developed through HEAL awards. supplement program not intended support research basic processes e.g. cultural attitudes) rather result strategies enable rapid implementation changes. total up 3.5 million available supplement existing HEAL grants cooperative agreements, up 1 year, evaluate strategies reduce stigma improve treatment, management services people chronic pain and/or OUD. Supplement requests not need address possible aspects stigma the context chronic pain or OUD, it encouraged appropriate consider piloting multi-layer, multicomponent interventions address stigma these contexts. Background 50 million adults the United States chronic daily pain. 19.6 million adults experience chronic pain interferes daily life work activities. Misuse addiction opioids, including prescription pain relievers, synthetic opioids such fentanyl, heroin become serious national health crisis. than130 people die every day an opioid-related drug overdose. Stigma be barrier treatment both people chronic pain the context being treated opioids also people OUD related painful conditions. Appropriate care needed address suffering people pain and/or OUD it critical address challenges associated stigma living these conditions, seeking care support pain management and/or recovery OUD. Stigma be barrier treatment both painful conditions substance abuse. Studies suggest people chronic pain are receiving who previously received opioid treatment face stigma their healthcare providers, family, friends, coworkers, health care system, society general. Stigma also major barrier implementation programs treatments chronic pain opioid disorder, such medication assisted treatment naloxone. People chronic pain problematic opioid report significant perceived stigma associated methadone buprenorphine treatment. Stigma also lead severe consequences people chronic pain long term opioid face acute opioid withdrawal due stigma. Chronic pain often stigmatized itself some approaches address opioid crisis led stigma related addictions be also applied people chronic pain. Stigma be challenge people pain and/or substance disorders, families, caregivers, clinicians. Reducing barriers care exist because stigma crucial care people for treatment effectiveness both chronic pain management and/or OUD. Research Objectives order effectively reduce stigma related the treatment chronic pain the context the opioid crisis and/or stigma related OUD, NIH encouraging submission applications supplements active grants provide evidence-based data inform strategies reduce stigma build resilience discrimination those chronic pain and/or OUD. High priority supplements will: Analyze strategies reduce stigma, discrimination prejudice related chronic pain management and/or OUD impact areas such prevention, management treatment access effectiveness recovery; existing psychometrically validated tools measure stigma only very compelling rationales, support development any new measurement tool. Research areas interest include: Prejudice care providers undermine treatment health QOL Strategies address stigma a variety contexts includes: among healthcare providers, workplace colleagues, emergency responders, family friends others; impact internalized anticipated stigma prevention, management, treatment recovery; adaption application existing theories health related stigma chronic pain and/or OUD reducing stigma; Rather the creation new measurement tools, use psychometrically validated measures stigma other populations e.g. HIV, mental illness) their application these populations. Analyses combinations approaches are known reduce discrimination prejudice a variety situations workplace- supervisors, colleagues; family friends, healthcare providers, emergency responders, community); Strategies address internalized stigma; Approaches build resilience discrimination prejudice these populations First stage development multicomponent approaches could expanded implemented large scale multicomponent research projects. Researchers find materials related the 2017 meeting: The Science Stigma Reduction that sponsored the National Institutes Health NIH) helpful. Description circumstances which administrative supplements available. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – Applications be accepted through 29 , 2020 , 5:00 PM local time applicant organization. NOSI expires May 30 , 2020 funding consideration, applicants must include ldquo;NOT-OD-20 101” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. parent award must active the application submitted. project budget periods must within currently approved project period the existing parent award. Applications non-responsive the terms this Notice be be considered this initiative. Review criteria, addition those described PA-18-591, include following: Does PI(s)/PD(s) expertise stigma, pain management and/or addiction appropriate the study stigma chronic pain opioid use? Does application propose engage people chronic pain and/or those OUD, providers, relevant stakeholders identifying key questions regarding stigma chronic pain management opioid and treatment? successful, does application the potential be implemented broadly Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-F-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Investigators planning submit application response the NOSI strongly encouraged contact appropriate Institute Center contact listed the NOSI discuss proposed project the context the parent award. Questions specific this NOSI should sent the contact listed the NOSI. nbsp; Inquiries Please direct inquiries to: Wendy B. Smith, MA, PhD, BCBAssociate DirectorOffice Behavioral Social Sciences Research OBSSR)Tel: 301-435-3718Email: smithwe@mail.nih.gov Wendy Weber, N.D., PhD., MPHNational Center Complementary Integrative Health NCCIH)Tel: 301-402-1272Email: mailto:weberwj@mail.nih.gov Alexis Bakos, PhD., MPH., RN National Cancer Institute NCI)Tel: 240-276-6609Email: alexis.bakos@nih.gov Leslie K. Derr, Ph.D.National Institute Arthritis Musculoskeletal Skin Diseases NIAMS)Tel: 301-402-4735 Email: derrl@mail.nih.gov M. Aklin, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-827-5909Email: aklinwm@nida.nih.gov Shelley Su, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-402-3869Email: shelley.su@nih.gov Yolanda Vallejo, PhD.National Institute Dental Craniofacial Research NIDCR)Tel: 301-827-4655Email: Yolanda.Vallejo@nih.gov Paul L. Kimmel, MDNational Institute Diabetes Digestive Kidney Diseases NIDDK)Tel: 301-594-1409Email:  Kimmelp@mail.nih.gov Durga Mohapatra, Ph.D.National Institute Neurological Disorders Stroke NINDS)Tel: 301-827-7403Email: dp.mohapatra@nih.gov Jacqueline Lloyd, PhD, MSWOffice Disease Prevention ODP)Tel: 301-827-5559Email: lloydj2@nih.gov

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA

The National Institutes of Health (NIH) and the Center for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.

This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.

This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Proposals submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.

Notice Special Interest Encourage Eligible NIH HEAL Initiative Awardees Apply Administrative Supplements Promote Training Clinical Research Pain Admin Supp – Clinical Trial Allowed) Notice Number: NOT-NS-20-044 Key Dates Release Date: April 10, 2020 First Available Due Date: 15, 2020 xpiration Date: July 31, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Center Complementary Integrative Health NCCIH) Office Strategic Coordination Common Fund) National Cancer Institute NCI) Purpose NIH Helping End Addiction Long TermSM (HEAL) Initiative aims improve our understanding, management treatment pain funding high quality scientific research this relatively understudied area medicine. the HEAL Initiative NIH meet long-term goals providing effective non-opioid options the treatment pain conditions innovative approaches treating opioid disorders, will necessary train new generation clinical pain researchers. Leveraging HEAL Initiative clinical research programs train novice researchers investigators new pain research the mechanics, techniques, best practices clinical pain research maximize impact HEAL funding both current future research endeavors. Increasing number individuals trained high quality clinical pain research a critical step toward ensuring highest impact HEAL, studies encompass broad range pain conditions have potential include, address needs of, positively impact diverse traditionally underserved patient populations. supplement existing HEAL clinical research awards intended allow exceptional graduate, post-doctoral e.g., MD, DO, DDS, PhD), early career individuals hereafter ldquo;candidates”) expand clinical pain research experience gain access the tools skills needed prepare for career clinical pain research. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – 15, 2020 July 1, 2020 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-NS-20-044” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one two years support only. Only existing awardees active HEAL Initiative Clinical Research Pain Management awards including EPPIC-Net, BACPAC, ERN, PRISM, HOPE programs) the HEAL associated Common Fund A2CPS program eligible apply. Applications supplement parent grants sites performing clinical studies be prioritized. project budget periods this supplement must within currently approved project period the parent award parent award must active not a cost extension the entire extent a supplement). A?dministrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-E-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Research Strategy section the application limited 5 pages two additional sections/attachments, PD/PI statement a candidate statement required descriptions below). Research Strategy Research Experience Plan; 5 pages) Describe plan the candidate’s research under supplement is within scope the funded parent HEAL Initiative research project. Identify research-related experiences be new the candidate how experiences contribute the candidate’s development a clinical pain researcher enhance ability contribute a meaningful to both current future clinical pain research projects. Describe goals will achieved during supplement award period. Examples goals include gaining experience new methodologies, assessment pain management pain management techniques the research setting, recruiting study participants, acquiring and/or analyzing data, preparing manuscripts publication, applying independent research funding. the first sentence the Research Strategy, applicants requested state the parent grant awarded a HEAL Initiative award to identify specific FOA the parent grant e.g., RFA-NS-19-016) facilitate processing the supplement application. additional sections/attachments required should attached PDF documents the ldquo;Other Attachments” field. PD/PI Statement 1 page) Describe qualifications track record the PD/PI the parent grant supporting co-investigators, applicable) mentoring graduate post-doctoral trainees clinical pain research. addition, describe specific plans mentorship this candidate during proposed research experience. Candidate Statement 3 pages) candidate should describe prior research experience, clinical experience the assessment, management, treatment pain, their accomplishments. candidate should also describe short- long-term research-related goals the ways which additional research experiences outlined this supplemental application help to achieve goals. Award Budget HEAL Initiative provide support up 50,000K per year a maximum 2 years up eight awards FY2020 FY2021. Awards be used provide salary support the candidate and/or funding relevant travel coursework. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Applications non-responsive terms this NOSI be be considered the NOSI initiative nbsp; Inquiries Please direct inquiries to: Rebecca Hommer, MDNational Institute Neurological Disorders amp; StrokeTelephone: 301-827-2257 Email: rebecca.hommer@nih.gov